<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>KOGENATE FS- antihemophilic factor (recombinant) 
			 </strong><br>Bayer HealthCare LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use KOGENATE FS safely and effectively.  See full prescribing information for KOGENATE FS.<br>KOGENATE FS (Antihemophilic Factor [Recombinant], Formulated with Sucrose)<br>For Intravenous Use, Lyophilized Powder for Reconstitution<br>Initial U.S. Approval: 1993</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Kogenate FS is an Antihemophilic Factor (Recombinant) indicated for:  (<a href="#section-1">1</a>)</p>
<dl>
<dt>•</dt>
<dd>Control and prevention of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes in adults and children with <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span>.</dd>
<dt>•</dt>
<dd>Peri-operative management in adults and children with <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span>.</dd>
<dt>•</dt>
<dd>Routine prophylaxis to prevent or reduce the frequency of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes in children with <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span> and to reduce the risk of joint damage in children without pre-existing joint damage.</dd>
<dt>•</dt>
<dd>Routine prophylaxis to prevent or reduce the frequency of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes in adults with <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span>. </dd>
</dl>
<p class="Highlighta">Kogenate FS is not indicated for the treatment of von Willebrand disease.  (<a href="#section-1">1</a>)</p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta"><span class="Bold">For intravenous use only.</span> </p>
<dl>
<dt>•</dt>
<dd>Each vial of Kogenate FS contains the labeled amount of recombinant factor VIII in international units (IU, unit).</dd>
<dt> </dt>
<dd>
<span class="Bold">Control and prevention of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes and peri-operative management </span>(<a href="#_Ref">2.1</a>)<span class="Bold">:</span>
</dd>
<dt>•</dt>
<dd>Dose (units) = body weight (kg) x desired factor VIII rise (IU/dL or % of normal) x 0.5 (IU/kg per IU/dL).</dd>
<dt>•</dt>
<dd>Titrate doses to patient’s clinical response.</dd>
<dt>•</dt>
<dd>Determine treatment frequency based on type of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episode.</dd>
</dl>
<p class="Highlighta"><span class="Bold">For routine prophylaxis in adults:</span> 25 units per kg three times a week (<a href="#_Ref">2.1</a>). </p>
<p class="Highlighta"><span class="Bold">For routine prophylaxis in children: </span>25 units per kg every other day (<a href="#_Ref">2.1</a>). </p>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Available as lyophilized powder in single use vials containing nominally 250, 500, 1000, 2000, and 3000 IU (<a href="#ID_9244b227-19c9-4c45-b54d-70ddbc31cb4e">3</a>). </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Do not use in patients who have life-threatening <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> to mouse or hamster protein or other constituents of the product (<a href="#ID_bfb09e43-41ab-44ac-9680-ce0c46acf503">4</a>). </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, are possible. Should symptoms occur, discontinue treatment with Kogenate FS and administer appropriate treatment (<a href="#ID_49b19eb9-2472-47d8-944a-eccaeea7e1ab">5.1</a>).</dd>
<dt>•</dt>
<dd>Development of activity-neutralizing antibodies can occur in patients receiving factor VIII-containing products, including Kogenate FS. If expected plasma factor VIII activity levels are not attained, or if <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is not controlled with an expected dose, perform an assay that measures factor VIII inhibitor concentration (<a href="#ID_6e20f754-380d-42f1-bffc-0418ee1df89c">5.2</a>).</dd>
<dt>•</dt>
<dd>When clotting is normalized by treatment with factor VIII, development of cardiovascular risk factors may be the same as the risk for non-hemophilic patients (<a href="#ID_fc965608-9330-43cb-8533-847e432fcafe">5.3</a>).</dd>
<dt>•</dt>
<dd>Monitor plasma factor VIII levels during infusions when indicated (<a href="#ID_d2803f50-0986-4c51-b511-1f73ed5f09a4">5.4</a>).</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions (≥4%) in clinical trials are inhibitor formation (neutralizing antibodies) in previously untreated and minimally treated patients (PUPs and MTPs), skin-associated <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> (e.g., <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>), infusion site reactions (e.g., <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>), and central venous access device (CVAD) associated <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Bayer HealthCare at 1-888-842-2937 or FDA at 1-800-FDA-1088 or </span><a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch.</a> </p>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Pregnancy: No human or animal data. Use only if clearly needed (<a href="#ID_73c5bea2-33db-4345-9a3d-9278647607b5">8.1</a>).</dd>
<dt>•</dt>
<dd>Pediatric Use: Higher factor VIII clearance may occur in children (4.4–16 years). Dose adjustment may be needed (<a href="#ID_60583a12-3bfa-4019-b5ad-83099b5b0ec0">8.4</a>).</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 8/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dose</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Preparation and Reconstitution</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Administration</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Neutralizing Antibodies</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Cardiovascular Risk Factors</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Monitoring Laboratory Tests</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h2><a href="#section-6.3" class="toc">Immunogenicity – Postmarketing Registries </a></h2>
<h1><a href="#section-7" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-7.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-7.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-7.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-7.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-7.5" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-8" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-9" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-9.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-9.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-9.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-10" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-10.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-10.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-11" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-12" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-13" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-14" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_1d3d99e0-7b1c-440b-ad90-f9ebdd5f2a84"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Kogenate<span class="Sup">®</span> FS is a recombinant antihemophilic factor indicated for:</p>
<dl>
<dt>•</dt>
<dd>Control and prevention of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes in adults and children with <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span>. </dd>
<dt>•</dt>
<dd>Surgical prophylaxis in adults and children with <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span>. </dd>
<dt>•</dt>
<dd>Routine <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> treatment to prevent or reduce the frequency of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes in children with hemophilia A and to reduce the risk of joint damage in children without pre-existing joint damage.</dd>
<dt>•</dt>
<dd>Routine <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> treatment to prevent or reduce the frequency of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes in adults with <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span>.</dd>
</dl>
<p>Kogenate FS is not indicated for the treatment of von Willebrand disease.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_9244b227-19c9-4c45-b54d-70ddbc31cb4e"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">For intravenous use after reconstitution only.</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_226fd1e6-3b85-4b34-81f4-1bd301e65b95"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dose</h2>
<dl>
<dt>•</dt>
<dd>Dosage and duration of treatment depend on the severity of the <span class="product-label-link" type="condition" conceptid="4120609" conceptname="Factor VIII deficiency">factor VIII deficiency</span>, the location and extent of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, and the patient’s clinical condition.<span class="Sup">1</span> Careful control of replacement therapy is especially important in cases of major surgery or life-threatening <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes.</dd>
<dt>•</dt>
<dd>Each vial of Kogenate FS has the recombinant factor VIII (rFVIII) potency in international units (IU, unit) stated on the label. One IU (unit), as defined by the World Health Organization standard for blood coagulation factor VIII, human, is approximately equal to the level of factor VIII activity found in 1 mL of fresh pooled human plasma. </dd>
<dt>•</dt>
<dd>The expected <span class="Italics">in vivo</span> peak increase in factor VIII level expressed as IU/dL (or % normal) can be estimated using the following formulas:</dd>
<dt> </dt>
<dd><span class="Bold">Dosage (units) = body weight (kg) x desired factor VIII rise (IU/dL or % of normal) x 0.5 (IU/kg per IU/dL)</span></dd>
<dt> </dt>
<dd><span class="Bold">or</span></dd>
<dt> </dt>
<dd><span class="Bold">IU/dL (or % normal) = Total Dose (IU)/body weight (kg) x 2 [IU/dL]/[IU/kg]</span></dd>
<dt>•</dt>
<dd>Titrate dose to the patient’s clinical response. Patients may vary in their pharmacokinetic (e.g., half-life, <span class="Italics">in vivo</span> recovery) and clinical responses to Kogenate FS.<span class="Sup">2,3,4</span> Although the dose can be estimated by the calculations above, it is highly recommended that appropriate laboratory tests, including serial factor VIII activity assays, are performed <span class="Italics">[see Warnings and Precautions (<a href="#ID_fc965608-9330-43cb-8533-847e432fcafe">5.3</a>) and Clinical Pharmacology (<a href="#ID_e35b2440-bc84-4151-90d1-b74b2caa8e0d">12.3</a>)]</span>.</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ccc35c50-e8e9-4849-8ac0-8b8b13426827"></a><a name="section-2.1.1"></a><p></p>
<h3><span class="Bold">Control and Prevention of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Episodes</span></h3>
<p class="First">A guide for dosing Kogenate FS for the control and prevention of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes is provided in Table 1. The goal of treatment is to maintain a plasma factor VIII activity level at or above the plasma levels (in % of normal or in IU/dL) outlined in Table 1. </p>
<a name="_Ref346111618"></a><table width="100%">
<caption><span>Table 1 Dosing for Control and Prevention of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Episodes </span></caption>
<col width="21%">
<col width="16%">
<col width="19%">
<col width="20%">
<col width="24%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">Type of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Episodes</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">Factor VIII Level Required</span><br><span class="Bold">(IU/dL or % of normal)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"><span class="Bold">Dose</span></p>
<p><span class="Bold">(IU/kg)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"><span class="Bold">Frequency of Doses</span></p>
<p><span class="Bold">(hours)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"><span class="Bold">Duration of Therapy</span></p>
<p><span class="Bold">(days)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First"><span class="Bold">Minor</span></p>
<p>Early <span class="product-label-link" type="condition" conceptid="76784" conceptname="Hemarthrosis">hemarthrosis</span>, minor muscle or oral bleeds.</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">20 – 40</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">10 – 20</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Repeat dose if there is evidence of further <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Until <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is resolved</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First"><span class="Bold">Moderate </span></p>
<p><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> into muscles, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> into the oral cavity, definite hemarthroses, and known <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>.</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">30 – 60</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">15 – 30</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">12 – 24</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Until <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is resolved</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top">
<p class="First"><span class="Bold">Major </span></p>
<p><span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">Gastrointestinal bleeding</span>. Intracranial, intra-abdominal or intrathoracic <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, central nervous system <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in the retropharyngeal or retroperitoneal spaces, or iliopsoas sheath.</p>
<p><span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fractures</span>.</p>
<p>Head <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>.</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">80 – 100</p></td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">Initial:    40 – 50 </p>
<p>Repeat:  20 – 25</p>
</td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">8 – 12</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Until <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is resolved</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_963b724e-4da7-4c60-b34a-270d32b1fb94"></a><a name="section-2.1.2"></a><p></p>
<h3><span class="Bold">Peri-operative Management</span></h3>
<p class="First">A guide for dosing Kogenate FS during surgery (perioperative management) is provided in Table 2. The goal of treatment is to maintain a plasma factor VIII activity level at or above the plasma level (in % of normal or in IU/dL) outlined in Table 2.</p>
<a name="_Ref346111641"></a><table width="100%">
<caption><span>Table 2 Dosing for Peri-operative Management </span></caption>
<col width="21%">
<col width="16%">
<col width="19%">
<col width="21%">
<col width="24%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">Type of Surgery</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">Factor VIII Level Required</span><br><span class="Bold">(IU/dL or % of normal)</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"><span class="Bold">Dose</span></p>
<p><span class="Bold">(IU/kg)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"><span class="Bold">Frequency of Doses</span></p>
<p><span class="Bold">(hours)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First"><span class="Bold">Duration of Therapy</span></p>
<p><span class="Bold">(days)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First"><span class="Bold">Minor</span></p>
<p>Including tooth extraction</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">30 – 60</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">15 – 30</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">12 – 24</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Until <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is resolved. </p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top">
<p class="First"><span class="Bold">Major</span></p>
<p>Examples include tonsillectomy, inguinal herniotomy, synovectomy, total knee replacement, craniotomy, osteosynthesis, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>.</p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">100</p></td>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First">50 </p>
<p>Pre-operatively to achieve 100% activity.</p>
</td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">6 – 12 to keep FVIII activity in desired range</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Until healing is complete. </p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4ed08ba3-3fec-4117-a5e9-f5609d3f54fa"></a><a name="section-2.1.3"></a><p></p>
<h3><span class="Bold">Routine Prophylaxis in Adults</span></h3>
<p class="First">The recommended dose for routine prophylaxis is 25 units per kg of body weight three times per week.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a288e64f-b14b-4b9f-95c6-b48b3a5c0cd0"></a><a name="section-2.1.4"></a><p></p>
<h3><span class="Bold">Routine Prophylaxis in Children</span></h3>
<p class="First">The recommended dose for routine prophylaxis is 25 units per kg of body weight every other day.<span class="Sup">5</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_1935aca2-8993-4bdc-9a1a-549f6c059657"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Preparation and Reconstitution</h2>
<p class="First">Kogenate FS is administered by intravenous injection after reconstitution. Patients should follow the specific reconstitution and administration procedures provided by their physicians. </p>
<p>Reconstitute and administer Kogenate FS with the components provided with each package. If any component of the package is opened or damaged, do not use this component.</p>
<p>Product reconstitution, administration, and handling of the administration set and needles must be done with caution because percutaneous puncture with a needle contaminated with blood can transmit infectious viruses, including HIV (AIDS) and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>. Place needles in a sharps container after single use. Discard all equipment, including any reconstituted Kogenate FS product, in an appropriate container. Obtain immediate medical attention if injury occurs.</p>
<p>For any questions about the handling, reconstitution and administration of Kogenate FS, contact Bayer Medical Communications at 1-888-84-BAYER (1-888-842-2937).</p>
<p>For instructions, patients should follow the recommendations in the FDA-Approved Patient Labeling. </p>
<p>The procedures below are provided as general guidelines for the reconstitution of Kogenate FS. </p>
<dl>
<dt>•</dt>
<dd>Work on a clean surface and wash hands thoroughly using soap and warm water before performing the procedures.</dd>
<dt>•</dt>
<dd>Reconstitute the product with the components provided with each package.  If any component of the package is opened or damaged, do not use this component.</dd>
<dt>•</dt>
<dd>Filter the reconstituted product to remove potential particulate matter in the solution. Filtering can be achieved by following the reconstitution steps as described below.</dd>
</dl>
<p><span class="Italics">Vacuum Transfer and Reconstitution</span></p>
<dl>
<dt>1.</dt>
<dd>Prepare the product under aseptic conditions.</dd>
<dt>2.</dt>
<dd>Warm the unopened diluent and the concentrate to a temperature not to exceed 37°C or 99°F.</dd>
<dt>3.</dt>
<dd>After removing the plastic flip-top caps (Fig. A), aseptically cleanse the rubber stoppers of both vials with alcohol, being careful not to handle the rubber stopper.</dd>
<dt>4.</dt>
<dd>Remove the protective cover from one end of the plastic transfer needle cartridge and penetrate the stopper of the diluent vial (Fig. B).</dd>
<dt>5.</dt>
<dd>Remove the remaining portion of the protective cover, invert the diluent vial and penetrate the rubber seal on the concentrate vial (Fig. C) with the needle at an angle.</dd>
<dt>6.</dt>
<dd>The vacuum will draw the diluent into the concentrate vial. Hold the diluent vial at an angle to the concentrate vial in order to direct the jet of diluent against the wall of the concentrate vial (Fig. C). Avoid excessive foaming. If the diluent does not get drawn into the vial, there is insufficient vacuum and the product should not be used.</dd>
<dt>7.</dt>
<dd>After removing the diluent vial and transfer needle (Fig. D), swirl until completely dissolved without creating excessive foaming (Fig. E).</dd>
<dt>8.</dt>
<dd>Re-swab top of reconstituted Kogenate FS vial with alcohol. Allow the stopper to air dry.</dd>
<dt>9.</dt>
<dd>After the concentrate powder is completely dissolved, withdraw the solution into the syringe through the filter needle that is supplied in the package (Fig. F). Replace the filter needle with the administration set provided and inject intravenously. </dd>
<dt>10.</dt>
<dd>If the same patient is to receive more than one vial, the contents of two vials may be drawn into the same syringe through a separate unused filter needle before attaching the vein needle.</dd>
</dl>
<div class="Figure">
<a name="id570246602"></a><img alt="Figures AF" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6d2e4c97-0fb1-4ba4-9c58-3de071029e9b&amp;name=image-11.jpg">
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_77414024-52b7-4e6b-abb2-f08d82fac73d"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Administration</h2>
<p class="First"><span class="Bold">For intravenous use after reconstitution only.</span></p>
<dl>
<dt>•</dt>
<dd>Inspect Kogenate FS visually for particulate matter and discoloration prior to administration, wherever solution and container permit. Do not use Kogenate FS if you notice any particulates or turbidity in the solution.</dd>
<dt>•</dt>
<dd>Store the reconstituted Kogenate FS at room temperature prior to administration, but administer it within 3 hours. </dd>
<dt>•</dt>
<dd>Administer Kogenate FS with the administration set provided with the product as it incorporates an in-line filter. In situations where the administration set provided cannot be used (e.g. when infusing into a peripheral or central line), use a separate filter compatible with Kogenate FS.</dd>
<dt> </dt>
<dd>
<span class="Underline">NOTE:</span> Do not use the administration set provided with the product to draw blood because it contains an in-line filter. When blood must be withdrawn prior to an infusion, use an administration set without a filter, then infuse Kogenate FS through an injection filter.  For any questions about compatible separate filters, contact Bayer Medical Communications at 1-888-84-BAYER (1-888-842-2937).</dd>
<dt>•</dt>
<dd>Administer Kogenate FS over a period of 1 to 15 minutes. Adapt the rate of administration to the response of each individual patient. Determine the pulse rate before and during administration of Kogenate FS. If there is a significant increase in pulse rate, reduce the rate of administration or temporarily halt the infusion allowing the symptoms to disappear promptly. </dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="ID_b75e8882-3dab-4959-9909-5763d0794e77"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Kogenate FS is available as a lyophilized powder in single use glass vials containing nominally 250, 500, 1000, 2000, and 3000 International Units (IU, unit).</p>
<p>Each vial of Kogenate FS is labeled with the recombinant antihemophilic factor activity expressed in IU per vial. This potency assignment employs a factor VIII concentrate standard that is referenced to a WHO International Standard for factor VIII concentrates, and is evaluated by appropriate methodology to ensure accuracy of the results.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_bfb09e43-41ab-44ac-9680-ce0c46acf503"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Kogenate FS is contraindicated in patients who have life-threatening <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> to mouse or hamster protein or other constituents of the product (sucrose, glycine, histidine, sodium, calcium chloride, polysorbate 80, imidazole, tri-n-butyl phosphate, and copper). </p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_e4bdf23b-c21d-4208-94aa-b645b782c4de"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_49b19eb9-2472-47d8-944a-eccaeea7e1ab"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> have been reported with Kogenate FS. Reported symptoms included <span class="product-label-link" type="condition" conceptid="4133326" conceptname="Facial swelling">facial swelling</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, decrease in blood pressure, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, tightness of the chest, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p>Kogenate FS contains trace amounts of mouse <span class="product-label-link" type="condition" conceptid="4104804" conceptname="Immunoglobulin G">immunoglobulin G</span> (MuIgG) and hamster (BHK) proteins <span class="Italics">[see Description (<a href="#ID_ddd577f6-2e0c-4dc7-938b-c475a59677ba">11</a>)].</span> Patients treated with this product may develop <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to these non-human mammalian proteins. </p>
<p>Discontinue Kogenate FS if symptoms occur and seek immediate emergency treatment.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6e20f754-380d-42f1-bffc-0418ee1df89c"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Neutralizing Antibodies</h2>
<p class="First">Neutralizing antibodies (inhibitors) have been reported following administration of Kogenate FS, predominantly in previously untreated patients (PUPs) <span class="Italics">[see Adverse Reactions (<a href="#ID_a6812b0e-32ce-4229-8276-1ac0bf319976">6</a>)]</span>.  Carefully monitor patients for the development of factor VIII inhibitors, using appropriate clinical observations and laboratory tests.<span class="Sup">6</span> If expected plasma factor VIII activity levels are not attained, or if <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is not controlled with an expected dose, perform an assay that measures factor VIII inhibitor concentration <span class="Italics">[see Warnings and Precautions (<a href="#ID_d2803f50-0986-4c51-b511-1f73ed5f09a4">5.4</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_fc965608-9330-43cb-8533-847e432fcafe"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Cardiovascular Risk Factors</h2>
<p class="First">Hemophilic patients with cardiovascular risk factors or diseases may be at the same risk to develop cardiovascular events as non-hemophilic patients when clotting has been normalized by treatment with factor VIII.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d2803f50-0986-4c51-b511-1f73ed5f09a4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Monitoring Laboratory Tests</h2>
<dl>
<dt>•</dt>
<dd>Monitor plasma factor VIII activity levels by the one-stage clotting assay to confirm the adequate factor VIII levels have been achieved and maintained, when clinically indicated <span class="Italics">[see Dosage and Administration (<a href="#_Ref">2</a>)].</span>
</dd>
<dt>•</dt>
<dd>Monitor for development of factor VIII inhibitors. Perform assay to determine if factor VIII inhibitor is present. If expected factor VIII activity plasma levels are not attained or if <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is not controlled with the expected dose of Kogenate FS, use Bethesda Units (BU) to titer inhibitors. <dl>
<dt>o</dt>
<dd>If the inhibitor is less than 10 BU per mL, the administration of additional Kogenate FS concentrate may neutralize the inhibitor and may permit an appropriate hemostatic response. </dd>
<dt>o</dt>
<dd>If inhibitor titers are above 10 BU per mL, adequate hemostasis may not be achieved. The inhibitor titer may rise following Kogenate FS infusion as a result of an anamnestic response to factor VIII. The treatment or prevention of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in such patients requires the use of alternative therapeutic approaches and agents.</dd>
</dl>
</dd>
</dl>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_a6812b0e-32ce-4229-8276-1ac0bf319976"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">Serious adverse reactions seen with Kogenate FS are systemic <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, including bronchospastic reactions and/or <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, and the development of high-titer inhibitors necessitating alternative treatments to factor VIII.</p>
<p>The most common adverse reactions (≥ 4%) observed in clinical trials were inhibitor formation in previously untreated patients (PUPs) and minimally treated patients (MTPs), skin-related <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> (e.g., <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>), infusion site reactions (e.g., <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>), and central venous access device (CVAD) associated <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f963cc26-e608-49bd-8368-fec24e6c3558"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in clinical practice. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f989ac39-a4c3-4d3c-8836-3f5f0638efa4"></a><a name="section-6.1.1"></a><p></p>
<h3><span class="Bold">Previously Treated Patients (PTPs)</span></h3>
<p class="First">During the open-label clinical studies conducted in 73 PTPs, there were 24 adverse reactions reported in the course of 24,936 infusions. </p>
<p>Adverse reactions reported by ≥ 4% of the patients are listed in Table 3 below.</p>
<a name="_RefID0EMQAG"></a><table width="100%">
<caption><span>Table 3 Adverse Reactions (AR) in Previously Treated Patients with Frequency of ≥ 4% (Age Range 12–59 years) </span></caption>
<col width="28%">
<col width="23%">
<col width="20%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">MedDRA Primary SOC</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Preferred Term</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">N = 73</span></p>
<p><span class="Bold">AR (%)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">Skin and Subcutaneous Tissue Disorders</span></p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">6 (8.2%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">General Disorders and Administration Site Conditions</span></p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Infusion site reactions</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3 (4.1%)</p></td>
</tr>
<tr class="Last"><td class="Botrule Lrule Rrule" colspan="3" valign="top"><p class="First"><span class="Bold">SOC = System Organ Class</span></p></td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_8bead4d7-2838-430e-a337-48c47b8411ec"></a><a name="section-6.1.2"></a><p></p>
<h3><span class="Bold">Previously Untreated Patients (PUPs) and Minimally Treated Patients (MTPs)</span></h3>
<p class="First">In clinical studies with pediatric PUPs and MTPs, there were 29 adverse reactions reported in the course of 9,389 infusions.</p>
<p>Adverse reactions reported by ≥ 4% of the patients are listed in Table 4 below.</p>
<a name="_Ref347127338"></a><table width="100%">
<caption><span>Table 4 Adverse Reactions (AR) in Previously Untreated Patients and Minimally Treated Patients with Frequency of ≥ 4% (Age Range 2–27 months)</span></caption>
<col width="28%">
<col width="23%">
<col width="20%">
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Denominator for <span class="Italics">de novo </span>inhibitors is N = 60, since one patient had a pre-existing inhibitor.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">MedDRA Primary SOC</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Preferred Term</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">N = 61</span></p>
<p><span class="Bold">AR (%)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">Skin and Subcutaneous Tissue Disorders</span></p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">10 (16%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">Blood and Lymphatic System Disorders</span></p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Factor VIII inhibition (neutralizing antibodies)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">9 (15%)<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">General Disorders and Administration Site Conditions</span></p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Infusion site reactions</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">4 (7%)</p></td>
</tr>
<tr class="Last"><td class="Botrule Lrule Rrule" colspan="3" valign="top"><p class="First"><span class="Bold">SOC = System Organ Class</span></p></td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_3f15a8b5-9383-44f4-b62c-a465622eb202"></a><a name="section-6.1.3"></a><p></p>
<h3><span class="Bold">Minimally Treated Patients (MTPs) in the Joint Outcome Study</span></h3>
<p class="First">In the Joint Outcome Study with pediatric MTPs treated with routine prophylaxis or episodic enhanced treatment for 5.5 years, 46 of the 65 randomized patients experienced adverse events over the study duration. </p>
<a name="_RefID0E5WAG"></a><table width="100%">
<caption><span>Table 5 Adverse Reactions in Minimally Treated Patients in the Joint Outcome Study (Age Range 0–6 years)</span></caption>
<col width="29%">
<col width="23%">
<col width="20%">
<col width="28%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>Three patients from the enhanced episodic arm had catheter removal.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">MedDRA Primary SOC</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Preferred Term</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Prophylaxis Arm </span></p>
<p><span class="Bold">N = 32</span><br><span class="Bold">AR (%)</span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top">
<p class="First"><span class="Bold">Enhanced Episodic Arm</span></p>
<p><span class="Bold">N = 33</span><br><span class="Bold">AR (%)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">Surgical and Medical Procedures</span></p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Central venous catheterization, Catheter removal</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">19 (59%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">18 (55%)<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></span></p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Central line <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">6 (19%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">6 (18%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">General Disorders and Administration Site Conditions</span></p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1 (3%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">4 (12%)</p></td>
</tr>
<tr class="Last"><td class="Botrule Lrule Rrule" colspan="4" valign="top"><p class="First"><span class="Bold">SOC = System Organ Class</span></p></td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_56ec19de-8815-41a3-ac3e-a832c3791439"></a><a name="section-6.1.4"></a><p></p>
<h3><span class="Bold">Immunogenicity </span></h3>
<p class="First">In clinical studies with 73 PTPs (defined as having more than 100 exposure days), one patient had a pre-existing inhibitor. In the other 72 patients, followed over 4 years, no <span class="Italics">de novo</span> inhibitors were observed. </p>
<p>In clinical studies with pediatric PUPs and MTPs, inhibitor development was observed in 9 out of 60 patients (15%), 6 were high titer<span class="Sup">1</span> (&gt;5 BU) and 3 were low-titer inhibitors. Inhibitors were detected at a median number of 7 exposure days (range 2 to 16 exposure days). </p>
<p>In the Joint Outcome Study with Kogenate FS,<span class="Sup">5</span><span class="Italics">de novo</span> inhibitor development was observed in 8 of 64 patients with negative baseline values (12.5%), 2 patients developed high titer<span class="Sup">1 </span>(&gt;5 BU) and were withdrawn from the study. Six patients developed low-titer inhibitors. Inhibitors were detected at a median number of 44 exposure days (range 5 to 151 exposure days).</p>
<p>Inhibitor data in PUPs have been collected in several postmarketing registries <span class="Italics">[see Postmarketing Experience (<a href="#ID_083e65ef-cd6b-4dd9-8033-a355e7a0bbda">6.2</a>)]</span>.</p>
<p>The detection of antibody formation is dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to Kogenate FS with the incidence of antibodies to other products may be misleading.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_083e65ef-cd6b-4dd9-8033-a355e7a0bbda"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">Because adverse reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following adverse reaction has been identified during post approval use of Kogenate FS:</p>
<p>Sensory System – <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Dysgeusia</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_d13195d3-22bc-46b1-a647-a94347fa8ea0"></a><a name="section-6.3"></a><p></p>
<h2>Immunogenicity – Postmarketing Registries </h2>
<p class="First">Data from the Research of Determinants of Inhibitor Development (RODIN) study<span class="Sup">7</span>, French National Registry (FranceCoag)<span class="Sup">8</span> and United Kingdom Haemophilia Centre Doctors’ Organisation (UKHCDO)<span class="Sup">9</span> registry reported an inhibitor development rate in PUPs for Kogenate FS of 38%, 50% and 35%, respectively, which is comparable to previously-reported inhibitor rates<span class="Sup">10</span> for FVIII products. These registry studies show a trend towards an increased risk of inhibitor development in PUPs, as compared to the reference rFVIII product.  A survey of Canadian <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span> centers<span class="Sup">11</span> (2005 to 2012) and available data from the  European Haemophilia Safety Surveillance (EUHASS)<span class="Sup"> 12</span> registry from 2009 to 2013, reported an inhibitor development rate in PUPs for Kogenate FS of 42% and 31%, respectively, with no statistically significant differences observed across FVIII products. </p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="ID_a77719e9-b859-4b3f-b3bf-c708f871c4c9"></a><a name="section-7"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_73c5bea2-33db-4345-9a3d-9278647607b5"></a><a name="section-7.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Italics">Pregnancy Category C.</span></p>
<p>Animal reproduction studies have not been conducted with Kogenate FS. It is also not known whether Kogenate FS can cause fetal harm when administered to a pregnant woman or affect reproductive capacity. Kogenate FS should be given to a pregnant woman only if clearly needed. </p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="ID_3db1dd28-1269-4e21-854b-38f6e77450b6"></a><a name="section-7.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">There is no information available on the effect of factor VIII replacement therapy on labor and delivery. Kogenate FS should be used only if clinically needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_d3367c03-b6db-4f60-8029-46ebcad56da8"></a><a name="section-7.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted into human milk. Because many drugs are excreted into human milk, caution should be exercised if Kogenate FS is administered to a nursing woman. </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_60583a12-3bfa-4019-b5ad-83099b5b0ec0"></a><a name="section-7.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and efficacy studies have been performed in previously untreated and minimally treated pediatric patients. Children, in comparison to adults, present higher factor VIII clearance values and, thus, lower half-life and recovery of factor VIII. This may be due to differences in body composition.<span class="Sup">13</span> Account for this difference in clearance when dosing or following factor VIII levels in the pediatric population <span class="Italics">[see Clinical Pharmacology (<a href="#ID_e35b2440-bc84-4151-90d1-b74b2caa8e0d">12.3</a>)]</span>. </p>
<p>Routine <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> treatment in children ages 0–2.5 years with no pre-existing joint damage has been shown to reduce spontaneous joint <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and the risk of joint damage. This data can be extrapolated to ages &gt;2.5–16 years for children who have no existing joint damage <span class="Italics">[see Clinical Studies (<a href="#ID_84c4af54-e2ac-4359-8ab2-cd727d58b821">14</a>)]</span>. </p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_5a839edc-cba0-4018-a785-d0cc33c45ce6"></a><a name="section-7.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Clinical studies with Kogenate FS did not include patients aged 65 and over. Dose selection for an elderly patient should be individualized.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_ddd577f6-2e0c-4dc7-938b-c475a59677ba"></a><a name="section-8"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Kogenate FS, Antihemophilic Factor (Recombinant), is a coagulation factor VIII produced by recombinant DNA technology. It is produced by Baby Hamster Kidney (BHK) cells into which the human factor VIII gene has been introduced.<span class="Sup">14</span> The cell culture medium contains Human Plasma Protein Solution (HPPS) and recombinant insulin, but does not contain any proteins derived from animal sources. Kogenate FS is a purified glycoprotein consisting of multiple peptides including an 80 kD and various extensions of the 90 kD subunit. It has the same biological activity as factor VIII derived from human plasma. No human or animal proteins, such as albumin, are added during the purification and formulation processes of Kogenate FS.</p>
<p>The purification process includes a solvent/detergent virus inactivation step in addition to the use of the purification methods of ion exchange chromatography, monoclonal antibody immunoaffinity chromatography, along with other chromatographic steps designed to purify recombinant factor VIII and remove contaminating substances. </p>
<p>Additionally, the manufacturing process was investigated for its capacity to decrease the infectivity of an experimental agent of transmissible spongiform <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> (TSE), considered as a model for the vCJD and CJD agents.<span class="Sup">15-19</span> Several of the individual production and raw material preparation steps in the Kogenate FS manufacturing process have been shown to decrease TSE infectivity of that experimental model agent. These TSE reduction steps include the Fraction II+III separation step for HPPS (6.0 log10) and an anion exchange chromatography step (3.6 log10).</p>
<p>Kogenate FS is formulated with the following as stabilizers (see Table 6) in the final container and is then lyophilized. The final product does not contain any preservative. It is a sterile, nonpyrogenic powder preparation for intravenous injection. Intravenous administration of sucrose contained in Kogenate FS will not affect blood glucose levels.</p>
<a name="_Ref346112042"></a><table width="100%">
<caption><span>Table 6 Stabilizers Contained in Kogenate FS Final Container</span></caption>
<col width="35%">
<col width="36%">
<col width="28%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Stabilizer</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">250 IU, 500 IU, 1000 IU</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">2000 IU</span>, <span class="Bold">3000 IU</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Sucrose</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">0.9–1.3%</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">0.9–1.2%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Glycine</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">21–25 mg/mL</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">20–24 mg/mL</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Histidine</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">18–23 mmol/L</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">17–22 mmol/L</p></td>
</tr>
</tbody>
</table>
<p>Table 7 lists the inactive ingredients/excipients also contained in the final product.</p>
<a name="_RefID0EXDBG"></a><table width="100%">
<caption><span>Table 7 Inactive Ingredients/Excipients</span></caption>
<col width="35%">
<col width="36%">
<col width="28%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Inactive Ingredient/Excipient</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">250 IU, 500 IU, 1000 IU</span></p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">2000 IU, 3000 IU</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Sodium</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">27–36  mEq/L</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">26–34 mEq/L</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Calcium</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">2.0–3.0 mmol/L</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">1.9–2.9 mmol/L</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Chloride</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">32–40 mEq/L</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">31–38 mEq/L</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Polysorbate 80</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">64–96 µg/mL</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">64–96 µg/mL</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Sucrose</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">28 mg/vial</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">52 mg/vial</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Imidazole, tri-n-butyl phosphate, and copper</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Trace amounts</p></td>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Trace amounts</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_01677236-447f-490a-816a-c3c9c4d54f51"></a><a name="section-9"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_c1d4b77b-a8cc-43f3-89b0-006cdee7e50c"></a><a name="section-9.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Kogenate FS temporarily replaces the missing clotting factor VIII that is needed for effective hemostasis.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="ID_779613ec-7e08-45c0-a467-9beefee865f2"></a><a name="section-9.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">The <span class="product-label-link" type="condition" conceptid="44809202" conceptname="Activated partial thromboplastin time">activated partial thromboplastin time</span> (aPTT) is prolonged in patients with <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span>. Determination of aPTT is a conventional <span class="Italics">in vitro</span> assay for biological activity of factor VIII. Treatment with Kogenate FS normalizes the aPTT over the effective dosing period.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_e35b2440-bc84-4151-90d1-b74b2caa8e0d"></a><a name="section-9.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The pharmacokinetic properties of Kogenate FS were investigated in two separate studies in adult and pediatric previously treated patients (PTPs). </p>
<p>Pharmacokinetic studies with Kogenate FS were conducted in 20 PTPs (ages 12 to 33 years) with severe <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span>. The pharmacokinetic parameters for Kogenate FS were measured in a randomized, crossover clinical trial with the predecessor KOGENATE product using a single dose administration of 50 IU per kg. After 24 weeks, the same dose of Kogenate FS was administered to the same patients. The recovery and half-life data for Kogenate FS were unchanged after 24 weeks of continued treatment with sustained efficacy and no evidence of factor VIII inhibition (see Table 8). </p>
<a name="_Ref346112226"></a><table width="100%">
<caption><span>Table 8 Pharmacokinetic Parameters for Kogenate FS Compared to KOGENATE</span></caption>
<col width="25%">
<col width="25%">
<col width="25%">
<col width="25%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2" valign="top"><p class="First"><span class="Bold">Parameter</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Kogenate FS</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">KOGENATE</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Initial PK </span><br><span class="Bold">(Mean±SD)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">PK at week 24 </span><br><span class="Bold">(Mean±SD)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Reference </span><br><span class="Bold">(Mean±SD)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">AUC (IU•h/dL) </p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1588.05 ± 344.32</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1487.08 ± 381.73</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1879.02 ± 412.32</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">C<span class="Sub">max</span> (IU/dL)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">114.95 ± 20.19</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">109.42 ± 20.09</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">127.40 ± 33.21</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Half-life (hr)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">13.74 ± 1.82</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">14.60 ± 4.38</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">14.07 ± 2.62</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">In Vivo Recovery <br>(IU/dL / IU/kg) </p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2.20 ± 0.34</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2.11 ± 0.37</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2.43 ± 0.60</p></td>
</tr>
</tbody>
</table>
<p>The pharmacokinetics of Kogenate FS were investigated in pediatric PTPs (4.4–18.1 years of age, average age 12).<span class="Sup">13</span> The pharmacokinetic parameters in children compared to adults show differences in higher clearance, lower incremental <span class="Italics">in vivo</span> factor VIII recovery and a shorter factor VIII half-life. The pharmacokinetic parameters are depicted in Table 9.</p>
<a name="_Ref346112286"></a><table width="100%">
<caption><span>Table 9 Pharmacokinetic Parameters for Kogenate FS in Children</span></caption>
<col width="54%">
<col width="46%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Parameter</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Mean (range)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">AUC (IU•h/dL)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1320.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Clearance (mL/h•kg)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">4.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Half-life (hr)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">10.7 (7.8–15.3)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">In Vivo Recovery (IU/dL / IU/kg) </p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.9 (1.25–2.76)</p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="ID_9424d4b0-fb92-4254-926d-23aa54cbba57"></a><a name="section-10"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_19b9df94-1738-4fdc-9bea-0d41fa26d664"></a><a name="section-10.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No studies have been conducted with Kogenate FS to assess its mutagenic or carcinogenic potential and impairment of fertility. By inference, the predecessor KOGENATE product and Kogenate FS would be expected to have equivalent mutagenic and carcinogenic potential. </p>
<p>The predecessor product did not demonstrate reverse mutation or chromosomal aberrations at doses substantially greater than the maximum expected clinical dose. <span class="Italics">In vivo</span> evaluation with the predecessor product in animals using doses ranging between 10 and 40 times the expected clinical maximum also indicated that the predecessor product did not possess a mutagenic potential. Long-term investigations of carcinogenic potential in animals have not been performed due to the immune response to heterologous proteins in all non-human mammalian species.</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="ID_c67d2f93-2c82-4fbf-a3de-a2615fcd3d09"></a><a name="section-10.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First">Preclinical studies evaluating Kogenate FS in <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span> with mice, rats, rabbits, and dogs demonstrated safe and effective restoration of hemostasis. Doses several fold higher than the recommended clinical dose (related to body weight) did not demonstrate any acute or subacute toxic effect for Kogenate FS in laboratory animals.</p>
<p>Kogenate FS has been shown to be comparable to the predecessor KOGENATE product with respect to its biochemical and physiochemical properties, as well as its non-clinical in vivo pharmacology and toxicology.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID_84c4af54-e2ac-4359-8ab2-cd727d58b821"></a><a name="section-11"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First"><span class="Bold"><span class="Italics">Previously Treated Patients (PTPs) Clinical Studies</span></span></p>
<p>A total of 73 patients with severe (≤ 2% FVIII) <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span>, ages 12–59, who had been previously treated with other recombinant or with plasma-derived AHF products, were treated up to 54 months in open label studies with Kogenate FS. A total of 5,684 <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes were treated during the studies; 92.7% of the bleeds were treated with one (79.7%) or two (13.0%) infusions. Patients could be treated with on-demand or prophylaxis. Regularly scheduled prophylaxis treatment represented 76% of all infusions (treatment regimens of 2–3 infusions per week). </p>
<p>A total of 30 patients received Kogenate FS for 41 surgical procedures during the PTP studies. There were both minor and major surgery types, 16 and 25 respectively. Efficacy was measured by the attending surgeon based on a comparison of estimated blood loss from experience with non-hemophilic patients undergoing similar procedures. The surgeon or treating physician assigned a rating to the hemostatic outcome according to 4 categories: “excellent (blood loss less than expected),? “good (blood loss as expected),? “moderate (blood loss more than expected),? or “none (uncontrolled <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>).? Hemostasis was rated as satisfactory (“excellent? or “good?) in all cases. </p>
<p><span class="Bold"><span class="Italics">Previously Untreated Patients (PUPs) and Minimally Treated Patients (MTPs) Clinical Study</span></span></p>
<p>Kogenate FS has been used in the treatment of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes in pediatric PUPs and MTPs with severe (&lt;2% FVIII) <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span>. There were 37 PUPs and 24 MTPs (defined as having equal to or less than 4 exposure days) treated with a total of 9,419 infusions of Kogenate FS for a follow up duration up to 3.1 years. A total of 1047 <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes were treated; the bleeds were treated with one (73%) or two (15%) infusions.</p>
<p>A total of 27 surgical procedures were performed in 22 patients during the PUPs and MTPs study. There were both minor and major surgery types, 21 and 6 respectively. The attending surgeon measured efficacy and assigned a rating to the hemostatic outcome according to 4 categories as described above for PTPs. Hemostasis was rated as satisfactory (“excellent? or “good?) in all cases. </p>
<p><span class="Bold"><span class="Italics">Adult Prophylaxis for <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Frequency Reduction</span></span></p>
<p>An ongoing, 3-year, multicenter, open-label, parallel-group, prospective, randomized, controlled clinical study of the effect of routine prophylaxis with Kogenate FS versus on-demand use on <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> frequency in adults and adolescents included 84 PTPs with severe <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">Hemophilia A</span> (FVIII level &lt; 1 IU/dL), age 15 to 50 years. Patients were matched at baseline on demographic and disease characteristics.  The median number of bleeds in the year before enrollment was 18.</p>
<p>Patients were randomized 1:1 to prophylaxis (25 units per kg three times a week) or on-demand use of Kogenate FS.  Escalation of the prophylaxis dose by 5 units per kg/infusion after years 1 and 2, up to a maximum of 35 units per kg/infusion, was allowed.</p>
<p><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> frequency was analyzed in the intent-to-treat population after a median follow-up period of 1.4 years.  Patients who received prophylaxis experienced statistically significantly fewer bleeds (p&lt;0.0001) compared to patients treated on-demand regardless of baseline subgroups examined including age, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> history, and presence or absence of target joints. The ratio of the mean <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> frequency was 15.2 (95% CI:  8.5, 27.2; p&lt;0.0001) for on-demand versus prophylaxis, indicating that patients who received on-demand treatment experienced on average 15.2 times as many bleeds compared to patients treated with prophylaxis. The mean annualized bleed rates (bleeds/subject/year) were 37 in the on-demand group versus 2 in the prophylaxis group. The median annualized bleed rate (bleeds/subject/year) in the on-demand group was 33 versus zero in the prophylaxis group.Most of the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> occurred in joints: the median joint bleed rate (joint bleeds/subject/year) was 24 in the on-demand group versus zero in the prophylaxis group. The mean annualized joint bleed rate was 29 in the on-demand group versus 2 in the prophylaxis group. </p>
<p>Twenty-two of 42 (52%) prophylaxis subjects experienced no <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, and 12 of 42 (29%) prophylaxis subjects experienced only 1–2 bleeds during the follow-up period.</p>
<p>Among prophylaxis patients the mean number of infusions/week was 2.8, and the median dose per prophylaxis infusion was 26 units per kg.</p>
<p><span class="Bold"><span class="Italics">Pediatric Prophylaxis for Joint Damage Risk Reduction</span></span></p>
<p>A total of 65 boys less than 30 months of age with severe <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span> (FVIII level ≤ 2 IU/dL) and with ≤ 2 bleeds into each index joint and normal baseline joint imaging, were observed for up to 5.5 years in a multicenter, open-label, prospective, randomized, controlled clinical study.<span class="Sup">5</span> Patients received either 25 IU per kg every other day (primary prophylaxis; n = 32) or at least 3 doses totaling a minimum of 80 IU per kg at the time of a <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episode (enhanced episodic; n = 33). Joint damage was evaluated by magnetic resonance imaging (MRI) or radiography, as well as the frequency of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes. Joint damage detected by MRI or radiography in the ankles, knees, and elbows (i.e., index joints) was statistically significantly lower (p = 0.002) for subjects receiving <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> therapy (7%) than for subjects receiving episodic therapy (42%). This corresponds to a 6.29-fold relative risk of joint damage for subjects treated with enhanced episodic therapy compared to prophylaxis. The mean rate of index joint <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhages</span> for subjects on episodic therapy was 4.89 bleeds per year, versus 0.63 bleeds per year observed in the prophylaxis arm. Three of 33 (9.1%) subjects in the episodic arm experienced recurrent life threatening bleeds (intracranial, gastrointestinal) compared to no subjects in the prophylaxis arm. On a per joint basis, joints in the regular prophylaxis arm were 8-fold more likely to remain damage-free than those in the episodic arm. Joint damage was most frequently observed in ankle joints and was detected at higher rates by MRI than by radiography. Ankles were also the index joint that demonstrated the highest frequency of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events in this study (left ankle, mean 2.7 <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhages</span>; right ankle, mean 2.6 <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhages</span>).</p>
<p>As shown in Table 10 below, the incidence of joint damage was statistically significantly lower in the <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> group as compared to the episodic treatment group when assessed by MRI, or either MRI or radiography, using predefined criteria (described below) for establishing joint damage. However, there was no statistically significant difference between the two groups when joint damage was assessed by radiography alone. </p>
<p>To evaluate joint damage, MRIs were scored using a scale developed by Nuss et al.,<span class="Sup">20</span> and X-rays were scored using the method of Pettersson et al.<span class="Sup">21</span> Both scales have been validated in various clinical trials and are routinely used for joint damage evaluation in hemophiliacs. Joint damage was defined as bone and/or cartilage damage including subchondral <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cysts</span>, erosions and cartilage loss with narrowing of joint space. This corresponded to a total MRI score of ≥ 7 or an X-ray score of ≥ 1 in any of the following categories: subchondral <span class="product-label-link" type="condition" conceptid="4209224" conceptname="Cyst">cysts</span>, erosions of joint surfaces or narrowing of joint spaces. Images were read separately by two independent radiologists centrally. Any discrepant reading was read by an independent third radiologist who was not aware of the initial reading results. The concordant reading of two out of three readers was used for analysis purposes.</p>
<a name="_RefID0ELYBG"></a><table width="100%">
<caption><span>Table 10 Subjects with Joint Damage (Subjects with Available Baseline and Endpoint Data)</span></caption>
<col width="16%">
<col width="16%">
<col width="17%">
<col width="17%">
<col width="17%">
<col width="17%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" rowspan="2" valign="top"><p class="First"><span class="Bold">Endpoint Assessment</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Prophylaxis</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Episodic Therapy </span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="1" valign="top"><p class="First"><span class="Bold">p-value</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Incidence (%)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Relative Risk (95% CI)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Incidence (%)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">Relative Risk (95% CI)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">MRI</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2/27 (7%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.17 (0.04, 0.67)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">13/29 (45%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">6.05 (1.50, 24.38)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.002</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">Radiography</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1/28 (4%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.19 (0.02, 1.55)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">5/27 (19%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">5.19 (0.65, 41.54)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.101</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">MRI or Radiography </span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2/30 (7%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.16 (0.04, 0.65)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">13/31 (42%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">6.29 (1.55, 25.55)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0.002</p></td>
</tr>
</tbody>
</table>
<p><span class="Italics">Relative Risk is the risk of damage to one or more index joints on the given therapy as compared to the other therapy.</span><br><span class="Italics">P-value is from the 2-sided Fisher Exact Test comparing the incidence of joint damage between treatment groups.</span></p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="ID_b218897f-8769-4ab0-8463-544bbf677666"></a><a name="section-12"></a><p></p>
<h1>15 REFERENCES</h1>
<dl>
<dt>1.</dt>
<dd>White GC, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J, for the Factor VIII and Factor IX Subcommittee of the Scientific and Standardization Committee of the International Society on <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span> and Haemostasis. Definitions in <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span>. <span class="Italics">Thromb Haemost</span> 85:560-75, 2001.</dd>
<dt>2.</dt>
<dd>Abildgaard CF, Simone JV, Corrigan JJ, et al: Treatment of <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span> with glycine-precipitated Factor VIII. <span class="Italics">N Engl J Med </span>275(9):471–5, 1966.</dd>
<dt>3.</dt>
<dd>Schwartz RS, Abildgaard CF, Aledort LM, et al: Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span>. Recombinant Factor VIII Study Group. <span class="Italics">N Engl J Med </span>323(26):1800-5, 1990.</dd>
<dt>4.</dt>
<dd>White GC 2nd, Courter S, Bray GL, et al: A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span>. The Recombinate Previously Treated Patient Study Group. <span class="Italics">Thromb Haemost </span>77(4):660-667, 1997.</dd>
<dt>5.</dt>
<dd>Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span>. <span class="Italics">N Engl J Med</span> 2007;357(6):535-44.</dd>
<dt>6.</dt>
<dd>Kasper CK: Complications of <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span> treatment: factor VIII inhibitors. <span class="Italics">Ann NY Acad Sci </span>614:97-105, 1991. </dd>
<dt>7.</dt>
<dd>Gouw SC, van den Berg HM, et al: Intensity of factor VIII treatment and inhibitor development in children with severe <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span>: the RODIN study. <span class="Italics">Blood</span> 121(20): 4046-4055, 2013.</dd>
<dt>8.</dt>
<dd>Calvez T, Chambost H, et al: Recombinant factor VIII products and inhibitor development in previously untreated boys with severe <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span>. <span class="Italics">Blood</span> 124(23): 3398-3408, 2014.</dd>
<dt>9.</dt>
<dd>Collins PW, Palmer BP, et al: Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span>, 2000-2011. <span class="Italics">Blood</span> 124(23): 3389-3397, 2014.</dd>
<dt>10.</dt>
<dd>Franchini M, Coppola A, et al: Systematic Review of the Role of FVIII Concentrates in Inhibitor Development in Previously Untreated Patients with Severe <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">Hemophilia A</span>: A 2013 Update. <span class="Italics">Semin Throm Hemost</span> (39): 752-766, 2013.</dd>
<dt>11.</dt>
<dd>Vezina C, Carcao M, et al: Incidence and risk factors for inhibitor development in previously untreated severe <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">haemophilia A</span> patients born between 2005 and 2010. <span class="Italics">Haemophilia</span> 20(6): 771-776, 2014.</dd>
<dt>12.</dt>
<dd>Fisher K, Lassila, R, et al. Inhibitor development in haemophilia according to concentrate: Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project. <span class="Italics">Thromb Haemost</span> 113.4, 2015.</dd>
<dt>13.</dt>
<dd>Barnes C, Lillicrap D, Pazmino-Canizares J, et al: Pharmacokinetics of recombinant factor VIII (Kogenate-FS<span class="Sup">®</span>) in children and causes of inter-patient pharmacokinetic variability. <span class="Italics">Haemophilia</span> 12 (Suppl. 4): 40-49, 2006.</dd>
<dt>14.</dt>
<dd>Lawn RM, Vehar GA: The molecular genetics of <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span>. <span class="Italics">Sci Am </span>254(3):48–54, 1986.</dd>
<dt>15.</dt>
<dd>Stenland CJ, et al: Partitioning of human and sheep forms of the pathogenic prion protein during the purification of therapeutic proteins from human plasma. <span class="Italics">Transfusion</span> 42(11):1497-500, 2002.</dd>
<dt>16.</dt>
<dd>Lee DC, Miller JL, Petteway SR: Pathogen safety of manufacturing processes for biological products: special emphasis on KOGENATE<span class="Sup">®</span> Bayer. <span class="Italics">Haemophilia </span>8(Suppl. 2):6-9, 2002.</dd>
<dt>17.</dt>
<dd>Lee DC, Stenland CJ, Miller JL, et al: A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> infectivity during the purification of plasma proteins. <span class="Italics">Transfusion</span> 41(4):449-55, 2001.</dd>
<dt>18.</dt>
<dd>Cai K, Miller JL, Stenland CJ, et al: Solvent-dependent precipitation of prion protein. <span class="Italics">Biochim Biophys Acta</span> 1597(1):28-35, 2002.</dd>
<dt>19.</dt>
<dd>Trejo SR, Hotta JA, Lebing W, et al: Evaluation of virus and prion reduction in a new intravenous immunoglobulin manufacturing process. <span class="Italics">Vox Sang</span> 84(3):176-87, 2003.</dd>
<dt>20.</dt>
<dd>Nuss R, Kilcoyne RF, Geraghty S, et al: MRI findings in haemophilic joints treated with radiosynoviorthesis with development of an MRI scale of joint damage. <span class="Italics">Haemophilia</span> 6:162-169, 2000.</dd>
<dt>21.</dt>
<dd>Pettersson H, Ahlberg A, Nilsson IM: A radiologic classification of <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span> <span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthropathy</span>. <span class="Italics">Clin Orthop Relat Res</span> 149:153-159, 1980.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_a6bbabbf-6220-4d49-b807-a9c6217d9c89"></a><a name="section-13"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First"><span class="Italics">How Supplied</span></p>
<p>Kogenate FS is available as a kit in the following single use glass vial sizes. A suitable volume of Sterile Water for Injection, USP, a double-ended transfer needle, a filter needle, and an administration set are provided in the kit.</p>
<table width="100%">
<col width="30%">
<col width="45%">
<col width="25%">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Kit NDC Number</span></p></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Approximate FVIII Activity (IU)</span></p></td>
<td class="Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Diluent (mL)</span></p></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">0026-3782-20</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">250</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">2.5</p></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">0026-3783-30</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">500</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">2.5</p></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">0026-3785-50</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">1000</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">2.5</p></td>
</tr>
<tr>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">0026-3786-60</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">2000</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">5.0</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0026-3787-70</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3000</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">5.0</p></td>
</tr>
</tbody>
</table>
<p>Actual factor VIII activity in IU is stated on the label of each Kogenate FS Vial.</p>
<p><span class="Underline">The product vial and diluent vial are not made with natural rubber latex.</span></p>
<p><span class="Italics">Storage and Handling</span></p>
<p><span class="Underline">Product as Packaged for Sale</span></p>
<dl>
<dt>•</dt>
<dd>Store Kogenate FS at +2°C to +8°C (36°F to 46°F) for up to 30 months from the date of manufacture. Within this period, Kogenate FS may be stored for a period of up to 12 months at temperatures up to +25°C or 77°F.</dd>
<dt>•</dt>
<dd>Record the starting date of room temperature storage on the unopened product carton. Once stored at room temperature, do not return the product to the refrigerator. The shelf-life then expires after storage at room temperature, or after the expiration date on the product vial, whichever is earlier. </dd>
<dt>•</dt>
<dd>Do not use Kogenate FS after the expiration date indicated on the vial. </dd>
<dt>•</dt>
<dd>Do not freeze. </dd>
<dt>•</dt>
<dd>Protect from extreme exposure to light and store the lyophilized powder in the carton prior to use.</dd>
</dl>
<p><span class="Underline">Product After Reconstitution</span></p>
<dl>
<dt>•</dt>
<dd>After reconstitution, store the Kogenate FS solution at room temperature and administer within 3 hours. </dd>
<dt>•</dt>
<dd>Use the administration set provided.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="ID_55e184ba-e9f8-4501-b6ad-a6838f0fe840"></a><a name="section-14"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<dl>
<dt>•</dt>
<dd>Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).</dd>
<dt>•</dt>
<dd>Advise patients to report any adverse reactions or problems following Kogenate FS administration to their physician or healthcare provider.</dd>
<dt>•</dt>
<dd>Allergic-type <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> have been reported with Kogenate FS. Warn patients of the early signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> [including <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span> (<span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> with <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>), <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">generalized urticaria</span>, tightness of the chest, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>] and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>. Advise patients to discontinue use of the product if these symptoms occur and seek immediate emergency treatment with resuscitative measures such as the administration of epinephrine and oxygen. </dd>
<dt>•</dt>
<dd>Inhibitor formation may occur at any time in the treatment of a patient with <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span>. Advise patients to contact their physician or treatment center for further treatment and/or assessment, if they experience a lack of clinical response to factor VIII replacement therapy, as this may be a manifestation of an inhibitor. </dd>
<dt>•</dt>
<dd>Advise patients to consult with their healthcare provider prior to travel. While traveling advise patients to bring an adequate supply of Kogenate FS based on their current regimen of treatment.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="ID_1d5586e2-2eae-4956-9206-80ba86f8e075"></a><a name="section-15"></a><p></p>
<p class="First"><span class="Bold"><span class="Italics">FDA-Approved Patient Labeling</span></span></p>
<p>Patient Information</p>
<p><span class="Bold">Kogenate FS (k?-jen-ate)</span></p>
<p><span class="Bold">Antihemophilic Factor (Recombinant)</span></p>
<p><span class="Bold">Formulated with Sucrose</span></p>
<p>This leaflet summarizes important information about Kogenate FS. Please read it carefully before using this medicine. This information does not take the place of talking with your healthcare provider, and it does not include all of the important information about Kogenate FS. If you have any questions after reading this, ask your healthcare provider.</p>
<p><span class="Bold">Do not attempt to self-infuse unless you have been taught how by your healthcare provider or <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span> center.</span></p>
<p><span class="Bold">What is Kogenate FS?</span></p>
<p>Kogenate FS is a medicine used to replace clotting factor (factor VIII or antihemophilic factor) that is missing in people with <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span> (also called “classic? <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span>). <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">Hemophilia A</span> is an inherited <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> disorder that prevents blood from clotting normally.</p>
<p>Kogenate FS is used to prevent or control <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in adults and children with <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span>. Your healthcare provider may give you Kogenate FS when you have surgery. Kogenate FS can reduce the number of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> episodes when used regularly (prophylaxis). Kogenate FS can reduce the risk of joint damage in children. </p>
<p>Kogenate FS is not used to treat von Willebrand Disease.</p>
<p><span class="Bold">Who should not use Kogenate FS?</span></p>
<p>You should not use Kogenate FS if you</p>
<dl>
<dt>•</dt>
<dd>are allergic to rodents (like mice and hamsters).</dd>
<dt>•</dt>
<dd>are allergic to any ingredients in Kogenate FS.</dd>
</dl>
<p>Tell your healthcare provider if you are pregnant or breast-feeding because Kogenate FS may not be right for you.</p>
<p><span class="Bold">What should I tell my healthcare provider before I use Kogenate FS?</span></p>
<p>Tell your healthcare provider about all of your medical conditions.</p>
<p>Tell your healthcare provider and pharmacist about all of the medicines you take, including all prescription and non-prescription medicines, such as over-the-counter medicines, supplements, or herbal remedies.</p>
<p>Tell your healthcare provider if you have been told you have heart disease or are at risk for heart disease.</p>
<p>Tell your healthcare provider if you have been told that you have inhibitors to factor VIII (because Kogenate FS may not work for you).</p>
<p><span class="Bold">What are the possible side effects of Kogenate FS?</span></p>
<p>You could have an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to Kogenate FS. Call your healthcare provider right away and stop treatment if you get</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span></dd>
<dt>•</dt>
<dd>tightness of the chest or throat</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span></dd>
<dt>•</dt>
<dd>light-headed, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></dd>
<dt>•</dt>
<dd>decrease in blood pressure</dd>
</dl>
<p>Your body can also make antibodies, called “inhibitors,? against Kogenate FS, which may stop Kogenate FS from working properly. Consult with your healthcare provider to make sure you are carefully monitored with blood tests for the development of inhibitors to factor VIII.</p>
<p>Other common side effects of Kogenate FS are</p>
<dl>
<dt>•</dt>
<dd>Local <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">injection site reactions</span> (<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, irritation at infusion site)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> from implanted injection device</dd>
</dl>
<p>Tell your healthcare provider about any side effect that bothers you or that does not go away.</p>
<p>Finding veins for injections may be difficult in young children. When frequent injections are required your child's healthcare provider may propose to have a device surgically placed under the skin to facilitate access to the bloodstream. These devices may result in <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. </p>
<p>These are not all the possible side effects with Kogenate FS. You can ask your healthcare provider for information that is written for healthcare professionals.</p>
<p><span class="Bold">How do I store Kogenate FS?</span></p>
<p>Do not freeze Kogenate FS.</p>
<p>Store Kogenate FS at +2°C to +8°C (36°F to 46°F) for up to 30 months from the date of manufacture. Within this period, Kogenate FS may be stored for a period of up to 12 months at temperatures up to +25°C or 77°F.</p>
<p>Record the starting date of room temperature storage clearly on the unopened product carton. Once stored at room temperature, do not return the product to the refrigerator. The product then expires after storage at room temperature, or after the expiration date on the product vial, whichever is earlier. Store vials in their original carton and protect them from extreme exposure to light. </p>
<p>Reconstituted product (after mixing dry products with wet diluent) must be used within 3 hours and cannot be stored.</p>
<p>Throw away any unused Kogenate FS after the expiration date.</p>
<p>Do not use reconstituted Kogenate FS if it is not clear to slightly cloudy and colorless.</p>
<p><span class="Bold">What else should I know about Kogenate FS and <span class="product-label-link" type="condition" conceptid="434007" conceptname="Hereditary factor VIII deficiency disease">hemophilia A</span>?</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed here. Do not use Kogenate FS for a condition for which it is not prescribed. Do not share Kogenate FS with other people, even if they have the same symptoms that you have.</p>
<p>This leaflet summarizes the most important information about Kogenate FS. If you would like more information, talk to your healthcare provider. You can ask your healthcare provider or pharmacist for information about Kogenate FS that was written for healthcare professionals.</p>
<p>Instructions for use</p>
<p><span class="Bold">How should I take Kogenate FS?</span></p>
<p><span class="Bold">Do not attempt to self-infuse unless you have been taught how by your healthcare provider or <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span> center.</span></p>
<p>See the step-by-step instructions for reconstituting Kogenate FS at the end of this leaflet and the specific infusion instruction leaflet provided.</p>
<p>You should always follow the specific instructions given by your healthcare provider. The steps listed below are general guidelines for using Kogenate FS. If you are unsure of the procedures, please call your healthcare provider before using.</p>
<p>Call your healthcare provider right away if <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> is not controlled after using Kogenate FS.</p>
<p>Your healthcare provider will prescribe the dose that you should take.</p>
<p>Your healthcare provider may need to take blood tests from time to time.</p>
<p>Talk to your healthcare provider before traveling. You should plan to bring enough Kogenate FS for your treatment during this time.</p>
<p>Carefully handle Kogenate FS. Dispose of all materials, including any leftover reconstituted Kogenate FS product, in an appropriate container.</p>
<p><span class="Bold">Reconstitution and use of Kogenate FS</span></p>
<p>Always work on a clean surface and wash your hands before performing the following procedure. Use only the components for reconstitution and administration that are provided with each package of Kogenate FS. If a package is opened or damaged, do not use this component. If these components cannot be used, please contact your healthcare provider. If you have any questions about Kogenate FS contact Bayer at 1-888-84-BAYER (1-888-842-2937).</p>
<p>1. Warm the unopened diluent and the concentrate to a temperature not to exceed 37°C or 99°F.</p>
<p>2. After removing the plastic flip-top caps (Fig. A), clean the rubber stoppers of both bottles with alcohol wipes. Be careful not to handle the rubber stopper.</p>
<div class="Figure">
<a name="id-2018374042"></a><img alt="Fig. A" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6d2e4c97-0fb1-4ba4-9c58-3de071029e9b&amp;name=image-01.jpg">
</div>
<p>3. Remove the cover from one end of the plastic transfer needle cartridge and insert into the stopper of the diluent bottle (Fig. B).</p>
<div class="Figure">
<a name="id-1637014210"></a><img alt="Fig. B" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6d2e4c97-0fb1-4ba4-9c58-3de071029e9b&amp;name=image-02.jpg">
</div>
<p>4. Remove the rest of the cover from the needle cartridge. Turn over the diluent bottle. With the needle at an angle, insert into the rubber seal on the concentrate bottle (Fig. C).</p>
<div class="Figure">
<a name="id318691499"></a><img alt="Fig. C" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6d2e4c97-0fb1-4ba4-9c58-3de071029e9b&amp;name=image-03.jpg">
</div>
<p>5. The vacuum will suck the diluent into the concentrate bottle. Hold the diluent bottle at an angle to the concentrate bottle in order to direct the stream of diluent against the wall of the concentrate bottle (Fig. C). Avoid too much foaming. If the diluent does not get into the bottle, the product should not be used.</p>
<p>6. Remove the diluent bottle and transfer needle (Fig. D). Gently, swirl the bottle until the Kogenate FS infusion liquid is dissolved. Be careful not to create foam (Fig. E). Throw away any liquid that is cloudy, the wrong color, or contains particles.</p>
<div class="Figure">
<a name="id-1920397960"></a><img alt="Figs. D and E" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6d2e4c97-0fb1-4ba4-9c58-3de071029e9b&amp;name=image-04.jpg">
</div>
<p>7. Clean the stopper of the Kogenate FS infusion liquid bottle with an alcohol wipe. Allow the stopper to air dry.</p>
<p>8. Using the filter needle from the infusion set, suck the infusion liquid into the syringe (Fig. F). Replace the filter needle with the vein needle from the infusion set and follow the specific instructions for infusion provided in the accompanying infusion set leaflet.</p>
<div class="Figure">
<a name="id303440379"></a><img alt="Fig. F" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6d2e4c97-0fb1-4ba4-9c58-3de071029e9b&amp;name=image-05.jpg">
</div>
<p>9. If the same patient is getting more than one bottle for an infusion, the contents of two infusion liquid bottles can be sucked into the same syringe using separate unused filter needles before attaching the vein needle.</p>
<p><span class="Bold">Rate of administration</span></p>
<p>The entire dose of Kogenate FS can usually be infused within 1 to 15 minutes. However, your healthcare provider will determine the rate of administration that is best for you.</p>
<p><span class="Bold">Resources at Bayer available to the patient:</span></p>
<p>For Adverse Reaction Reporting contact:</p>
<p>Bayer Medical Communications 1-888-84-BAYER (1-888-842-2937)</p>
<p>Contact Bayer to receive more product information:</p>
<p>Kogenate FS Customer Service 1-888-606-3780</p>
<p>Bayer Reimbursement HELPline 1-800-288-8374</p>
<p>For more information, visit www.kogenatefs.com</p>
<p>Bayer HealthCare LLC<br>Whippany, NJ  07981<br>U.S. License No. 8</p>
<p>(License Holder: Bayer Corporation) </p>
<p>http://www.kogenatefs.com</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_f2cc2398-4f71-4093-b8c0-f9689b7b58e0"></a><a name="section-16"></a><p></p>
<h1>Kogenate FS Carton 250 IU</h1>
<p class="First"><span class="Bold">250 IU Range</span></p>
<p><span class="Bold">NDC </span>0026-3782-20</p>
<p><span class="Bold">Kogenate FS</span><br>Antihemophilic<br>Factor<br>(Recombinant)</p>
<p><span class="Bold">Formulated with</span><br><span class="Bold">Sucrose</span></p>
<div class="Figure">
<a name="id-643509465"></a><img alt="250 IU Range Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6d2e4c97-0fb1-4ba4-9c58-3de071029e9b&amp;name=image-06.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_f8238f73-a81e-4765-af1c-401004312561"></a><a name="section-17"></a><p></p>
<h1>Kogenate FS Carton 500 IU</h1>
<p class="First"><span class="Bold">500 IU Range</span></p>
<p><span class="Bold">NDC </span>0026-3783-30</p>
<p><span class="Bold">Kogenate FS</span><br>Antihemophilic<br>Factor<br>(Recombinant)</p>
<p><span class="Bold">Formulated with</span><br><span class="Bold">Sucrose</span></p>
<div class="Figure">
<a name="id-348639464"></a><img alt="500 IU Range Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6d2e4c97-0fb1-4ba4-9c58-3de071029e9b&amp;name=image-07.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_5ab27de3-7765-496f-a76a-85e658cfbecb"></a><a name="section-18"></a><p></p>
<h1>Kogenate FS Carton 1000 IU</h1>
<p class="First"><span class="Bold">1000 IU Range</span></p>
<p><span class="Bold">NDC </span>0026-3785-50</p>
<p><span class="Bold">Kogenate FS</span><br>Antihemophilic<br>Factor<br>(Recombinant)</p>
<p><span class="Bold">Formulated with</span><br><span class="Bold">Sucrose</span></p>
<div class="Figure">
<a name="id2751"></a><img alt="1000 IU Range Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6d2e4c97-0fb1-4ba4-9c58-3de071029e9b&amp;name=image-08.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_1196ce5a-0b06-46a3-9f0d-f9c8d0fb69c1"></a><a name="section-19"></a><p></p>
<h1>Kogenate FS Carton 2000 IU</h1>
<p class="First"><span class="Bold">2000 IU Range</span></p>
<p><span class="Bold">NDC </span>0026-3786-60</p>
<p><span class="Bold">Kogenate FS</span><br>Antihemophilic<br>Factor<br>(Recombinant)</p>
<p><span class="Bold">Formulated with</span><br><span class="Bold">Sucrose</span></p>
<div class="Figure">
<a name="id2776"></a><img alt="2000 IU Range Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6d2e4c97-0fb1-4ba4-9c58-3de071029e9b&amp;name=image-09.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_41356f28-0bc2-47cb-bc02-c2de7abddcb1"></a><a name="section-20"></a><p></p>
<h1>Kogenate FS Carton 3000 IU</h1>
<p class="First"><span class="Bold">3000 IU Range</span></p>
<p><span class="Bold">NDC </span>0026-3787-70</p>
<p><span class="Bold">Kogenate FS</span><br>Antihemophilic<br>Factor<br>(Recombinant)</p>
<p><span class="Bold">Formulated with</span><br><span class="Bold">Sucrose</span></p>
<div class="Figure">
<a name="id2801"></a><img alt="3000 IU Range Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=6d2e4c97-0fb1-4ba4-9c58-3de071029e9b&amp;name=image-10.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>KOGENATE FS 		
					</strong><br><span class="contentTableReg">antihemophilic factor (recombinant) kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PLASMA DERIVATIVE</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0026-3785</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0026-3785-50</td>
<td class="formItem">1  in 1 BOX; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 VIAL, SINGLE-USE </td>
<td class="formItem">2.5 mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 VIAL </td>
<td class="formItem">2.5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>KOGENATE FS 		
					</strong><br><span class="contentTableReg">antihemophilic factor (recombinant) injection, powder, lyophilized, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0026-4785</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT</strong> (ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT) </td>
<td class="formItem">ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT</td>
<td class="formItem">1000 [iU]  in 2.5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CHLORIDE ION</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>COPPER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLYCINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HISTIDINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM POLYMETAPHOSPHATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TRI-N-BUTYL PHOSPHATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0026-4785-01</td>
<td class="formItem">2.5 mL in 1 VIAL, SINGLE-USE; Combination Product Type = C102836</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103332</td>
<td class="formItem">06/26/2000</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>DILUENT 		
					</strong><br><span class="contentTableReg">water solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0026-0425</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0026-0425-02</td>
<td class="formItem">2.5 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103332</td>
<td class="formItem">06/26/2000</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103332</td>
<td class="formItem">06/26/2000</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>KOGENATE FS 		
					</strong><br><span class="contentTableReg">antihemophilic factor (recombinant) kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PLASMA DERIVATIVE</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0026-3783</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0026-3783-30</td>
<td class="formItem">1  in 1 BOX; Combination Product Type = C102836</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 VIAL, SINGLE-USE </td>
<td class="formItem">2.5 mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 VIAL </td>
<td class="formItem">2.5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>KOGENATE FS 		
					</strong><br><span class="contentTableReg">antihemophilic factor (recombinant) injection, powder, lyophilized, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0026-4783</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT</strong> (ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT) </td>
<td class="formItem">ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT</td>
<td class="formItem">500 [iU]  in 2.5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CHLORIDE ION</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>COPPER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLYCINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HISTIDINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM POLYMETAPHOSPHATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TRI-N-BUTYL PHOSPHATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0026-4783-01</td>
<td class="formItem">2.5 mL in 1 VIAL, SINGLE-USE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103332</td>
<td class="formItem">06/26/2000</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>DILUENT 		
					</strong><br><span class="contentTableReg">water solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0026-0425</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0026-0425-02</td>
<td class="formItem">2.5 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103332</td>
<td class="formItem">06/26/2000</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103332</td>
<td class="formItem">06/26/2000</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>KOGENATE FS 		
					</strong><br><span class="contentTableReg">antihemophilic factor (recombinant) kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PLASMA DERIVATIVE</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0026-3782</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0026-3782-20</td>
<td class="formItem">1  in 1 BOX; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 VIAL, SINGLE-USE </td>
<td class="formItem">2.5 mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 VIAL </td>
<td class="formItem">2.5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>KOGENATE FS 		
					</strong><br><span class="contentTableReg">antihemphilic factor (recombinant) injection, powder, lyophilized, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0026-4782</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT</strong> (ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT) </td>
<td class="formItem">ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT</td>
<td class="formItem">250 [iU]  in 2.5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CHLORIDE ION</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>COPPER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLYCINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HISTIDINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM POLYMETAPHOSPHATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TRI-N-BUTYL PHOSPHATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0026-4782-01</td>
<td class="formItem">2.5 mL in 1 VIAL, SINGLE-USE; Combination Product Type = C102836</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103332</td>
<td class="formItem">06/26/2000</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>DILUENT 		
					</strong><br><span class="contentTableReg">water solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0026-0425</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0026-0425-02</td>
<td class="formItem">2.5 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103332</td>
<td class="formItem">06/26/2000</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103332</td>
<td class="formItem">06/26/2000</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>KOGENATE FS 		
					</strong><br><span class="contentTableReg">antihemophilic factor (recombinant) kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PLASMA DERIVATIVE</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0026-3786</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0026-3786-60</td>
<td class="formItem">1  in 1 BOX; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 VIAL, SINGLE-USE </td>
<td class="formItem">5 mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 VIAL </td>
<td class="formItem">5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>KOGENATE FS 		
					</strong><br><span class="contentTableReg">antihemophilic factor (recombinant) injection, powder, lyophilized, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0026-4786</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT</strong> (ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT) </td>
<td class="formItem">ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT</td>
<td class="formItem">2000 [iU]  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CHLORIDE ION</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>COPPER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLYCINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HISTIDINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM POLYMETAPHOSPHATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TRI-N-BUTYL PHOSPHATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0026-4786-01</td>
<td class="formItem">5 mL in 1 VIAL, SINGLE-USE; Combination Product Type = C102836</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103332</td>
<td class="formItem">06/07/2007</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>DILUENT 		
					</strong><br><span class="contentTableReg">water solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0026-0426</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0026-0426-50</td>
<td class="formItem">5 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103332</td>
<td class="formItem">06/07/2007</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103332</td>
<td class="formItem">06/07/2007</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>KOGENATE FS 		
					</strong><br><span class="contentTableReg">antihemophilic factor (recombinant) kit</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PLASMA DERIVATIVE</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0026-3787</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0026-3787-70</td>
<td class="formItem">1  in 1 BOX; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Quantity of Parts</td></tr>
<tr>
<th scope="col" width="5" class="formTitle">Part #</th>
<th scope="col" class="formTitle">Package Quantity</th>
<th scope="col" class="formTitle">Total Product Quantity</th>
</tr>
<tr class="formTableRowAlt">
<td width="5" class="formItem"><strong>Part 1</strong></td>
<td class="formItem">1 VIAL, SINGLE-USE </td>
<td class="formItem">5 mL</td>
</tr>
<tr class="formTableRow">
<td width="5" class="formItem"><strong>Part 2</strong></td>
<td class="formItem">1 VIAL </td>
<td class="formItem">5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 1 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>KOGENATE FS 		
					</strong><br><span class="contentTableReg">antihemophilic factor (recombinant) injection, powder, lyophilized, for solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0026-4787</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT</strong> (ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT) </td>
<td class="formItem">ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT</td>
<td class="formItem">3000 [iU]  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CALCIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CHLORIDE ION</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>COPPER</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>GLYCINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>HISTIDINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM POLYMETAPHOSPHATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SUCROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TRI-N-BUTYL PHOSPHATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0026-4787-01</td>
<td class="formItem">5 mL in 1 VIAL, SINGLE-USE; Combination Product Type = C102836</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103332</td>
<td class="formItem">07/31/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellspacing="0" cellpadding="5">
<tr><td class="contentTableTitle">Part 2 of 2</td></tr>
<tr><td class="contentTableTitle">
<strong>DILUENT 		
					</strong><br><span class="contentTableReg">water solution</span>
</td></tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0026-0426</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0026-0426-50</td>
<td class="formItem">5 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103332</td>
<td class="formItem">07/31/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103332</td>
<td class="formItem">07/31/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Bayer HealthCare LLC
							(127769128)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Bayer HealthCare LLC</td>
<td class="formItem"></td>
<td class="formItem">127769128</td>
<td class="formItem">MANUFACTURE(0026-3785, 0026-3783, 0026-3782, 0026-3786, 0026-3787), API MANUFACTURE(0026-3785, 0026-3783, 0026-3782, 0026-3786, 0026-3787)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>ee693b19-33d8-48df-bdf6-48526f47bb14</div>
<div>Set id: 6d2e4c97-0fb1-4ba4-9c58-3de071029e9b</div>
<div>Version: 8</div>
<div>Effective Time: 20150811</div>
</div>
</div> <div class="DistributorName">Bayer HealthCare LLC</div></p>
</body></html>
